- Plasma p-tau217 concentrations rise with advancing clinical stage, markedly so in Aβ positive participants.
- In Aβ positive individuals, higher baseline p-tau217 correlates with worse MMSE, CDR-SB and ADAS-Cog13 and predicts greater subsequent decline.
- Increases in p-tau217 associate with concurrent worsening in ADAS-Cog13 and CDR-SB; within-person increases linked to ADAS-Cog13 decline, weaker effects in Aβ negative.
Int Psychogeriatr. 2026 Nov 11:100311. doi: 10.1016/j.inpsyc.2026.100311. Online ahead of print.
ABSTRACT
OBJECTIVE: Plasma p-tau217 is a well-established biomarker of Alzheimer disease (AD) pathology, but its relationship with cognitive status and longitudinal cognitive change remains less well characterized. We investigated the clinical relevance of plasma p-tau217 as a blood-based biological correlate of cognitive status and change in AD.
METHODS: We included 1147 participants from the Alzheimer’s Disease Neuroimaging Initiative (ADNI) with available plasma biomarkers and amyloid-β (Aβ) status determined by amyloid PET or cerebrospinal fluid Aβ42. Cross-sectional associations between plasma p-tau217 and cognitive performance were evaluated across clinical stages and by Aβ status. Longitudinal associations between baseline plasma p-tau217 and subsequent cognitive change, as well as between changes in p-tau217 and changes in cognition, were assessed using linear mixed-effects models and correlation analyses. Baseline to last follow-up change correlations and separated within-person from between-person associations were also analyzed.
RESULTS: Plasma p-tau217 were higher at more advanced clinical stages, particularly among Aβ+ participants. In the Aβ positive group, higher p-tau217 was associated with poorer baseline MMSE, CDR-SB, and ADAS-Cog13 scores (partial ρ = -0.46, 0.52, and 0.55, respectively). Higher baseline p-tau217 was associated with greater subsequent worsening on all three measures at nominal P < 0.05. Increases in p-tau217 were associated with concurrent worsening in ADAS-Cog13 and CDR-SB (P = 0.001 and P = 0.011, respectively, but not MMSE. Exploratory analyses identified a within-person association between p-tau217 increases and ADAS-Cog13 worsening. Associations were less consistent among Aβ- participants.
CONCLUSION: Plasma p-tau217 was associated with cognitive impairment and longitudinal cognitive change, particularly among Aβ+ participants. These findings support plasma p-tau217 as a potential blood-based biological correlate of cognitive status and longitudinal cognitive change in AD.
PMID:43009349 | DOI:10.1016/j.inpsyc.2026.100311
Share Evidence Blueprint
Save to Google Notes

Search Google Scholar
⭐ My Revision List

